[144] ANI Pharmaceuticals, Inc. SEC Filing
ANI Pharmaceuticals (ANIP) Form 144 shows a proposed sale of 14,675 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $1,304,170.19, and an approximate sale date of 08/18/2025. The issuer has 21,688,772 shares outstanding. The filing lists acquisition details for the securities being sold: 1,072 shares vested 12/20/2021, 3,554 shares vested 08/31/2022, and 10,049 shares vested 05/09/2023, all described as restricted stock vesting under a registered plan for services rendered. The filing also records a sale on 08/18/2025 by Jeanne A Thoma of 6,865 shares for gross proceeds of $616,223.68. The filer attests there is no undisclosed material adverse information.
ANI Pharmaceuticals (ANIP) 鈥� Il modulo Form 144 indica la proposta di vendita di 14.675 azioni ordinarie tramite Morgan Stanley Smith Barney, per un valore complessivo di mercato di $1.304.170,19, con data di vendita prevista intorno al 18/08/2025. L'emittente ha in circolazione 21.688.772 azioni. La comunicazione specifica i dettagli di acquisizione dei titoli venduti: 1.072 azioni maturate il 20/12/2021, 3.554 azioni maturate il 31/08/2022 e 10.049 azioni maturate il 09/05/2023, tutte descritte come azioni vincolate maturate nell'ambito di un piano registrato per prestazioni rese. Il documento registra inoltre una vendita effettuata il 18/08/2025 da Jeanne A. Thoma di 6.865 azioni per proventi lordi di $616.223,68. Il dichiarante attesta l'assenza di informazioni materiali avverse non divulgate.
ANI Pharmaceuticals (ANIP) 鈥� El Formulario 144 muestra una propuesta de venta de 14.675 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney, con un valor de mercado agregado de $1.304.170,19, y una fecha aproximada de venta del 18/08/2025. El emisor tiene 21.688.772 acciones en circulaci贸n. La presentaci贸n detalla la adquisici贸n de los valores vendidos: 1.072 acciones adquiridas el 20/12/2021, 3.554 acciones adquiridas el 31/08/2022 y 10.049 acciones adquiridas el 09/05/2023, todas descritas como acciones restringidas que vencen bajo un plan registrado por servicios prestados. El documento tambi茅n registra una venta el 18/08/2025 por parte de Jeanne A. Thoma de 6.865 acciones por ingresos brutos de $616.223,68. El declarante afirma que no existen informaciones materiales adversas no divulgadas.
ANI Pharmaceuticals (ANIP) 鈥� Form 144鞐愲姅 Morgan Stanley Smith Barney毳� 韱淀暣 14,675 氤错喌欤茧ゼ 毵り皝頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜臧� $1,304,170.19, 鞓堨儊 毵り皝鞚检潃 2025-08-18搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氚滍枆欤茧姅 齑� 21,688,772欤检瀰雼堧嫟. 鞝滌稖靹滊鞐愲姅 毵り皝霅橂姅 歃濌秾鞚� 旆摑 雮挫棴鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟: 1,072欤�(2021-12-20 旆摑), 3,554欤�(2022-08-31 旆摑), 10,049欤�(2023-05-09 旆摑)搿�, 氇憪 靹滊箘鞀� 鞝滉车鞚� 雽�臧�搿� 霌彪霅� 頂岆灉鞐� 霐半澕 鞝滍暅欤缄皜 氩犾姢韺呺悳 瓴冹溂搿� 靹る獏霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 臧欖潃 靹滊鞐� Jeanne A. Thoma臧� 2025-08-18鞐� 6,865欤茧ゼ 毵り皝頃橃棳 齑� 靾橃澋 $616,223.68鞚� 鞏混棃雼り碃 旮半霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 歆勳垹頃╇媹雼�.
ANI Pharmaceuticals (ANIP) 鈥� Le formulaire 144 indique une proposition de vente de 14 675 actions ordinaires via Morgan Stanley Smith Barney, pour une valeur de march茅 totale de $1 304 170,19, et une date approximative de vente au 18/08/2025. L'茅metteur compte 21 688 772 actions en circulation. Le d茅p么t pr茅cise les modalit茅s d'acquisition des titres c茅d茅s : 1 072 actions acquises le 20/12/2021, 3 554 actions acquises le 31/08/2022 et 10 049 actions acquises le 09/05/2023, toutes d茅crites comme des actions restreintes acquises dans le cadre d'un plan enregistr茅 pour prestations de services. Le dossier enregistre 茅galement une vente le 18/08/2025 par Jeanne A. Thoma de 6 865 actions pour un produit brut de $616 223,68. Le d茅clarant atteste qu'il n'existe aucune information d茅favorable mat茅rielle non divulgu茅e.
ANI Pharmaceuticals (ANIP) 鈥� Das Formular 144 zeigt einen geplanten Verkauf von 14.675 Stammaktien 眉ber Morgan Stanley Smith Barney mit einem gesamten Marktwert von $1.304.170,19 und einem voraussichtlichen Verkaufstermin um den 18.08.2025. Der Emittent hat 21.688.772 ausstehende Aktien. Die Einreichung listet Erwerbsdetails der verkauften Wertpapiere auf: 1.072 Aktien, erworben am 20.12.2021; 3.554 Aktien, erworben am 31.08.2022; und 10.049 Aktien, erworben am 09.05.2023 鈥� alle als eingeschr盲nkte Aktien beschrieben, die unter einem registrierten Plan f眉r erbrachte Dienstleistungen vesten. Die Einreichung verzeichnet zudem einen Verkauf am 18.08.2025 durch Jeanne A. Thoma von 6.865 Aktien f眉r Bruttoerl枚se von $616.223,68. Der Einreicher versichert, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
- Full acquisition history provided showing vesting dates and amounts for the shares to be sold
- Broker and estimated market value disclosed, improving transparency about the proposed sale
- Seller attestation that no undisclosed material adverse information is known
- None.
Insights
TL;DR Insider proposes to sell vested restricted shares; transaction appears routine and consistent with employment-related equity vesting.
The filing documents a routine Rule 144 notice for the proposed sale of 14,675 ANIP common shares via Morgan Stanley with an indicated aggregate market value of $1,304,170.19 and an approximate sale date of 08/18/2025. Acquisition history shows these shares resulted from restricted stock vesting under a registered plan and were granted as consideration for services, which aligns with standard executive/employee equity compensation patterns. The contemporaneous record of a separate sale by Jeanne A Thoma of 6,865 shares for $616,223.68 is disclosed. There is no information here about any undisclosed material events or change in issuer fundamentals; the filing is procedural under Rule 144.
TL;DR Equity dispositions tied to vesting are disclosed appropriately; no governance concerns are evident from this filing alone.
The Form 144 specifies that the securities to be sold were acquired through restricted stock vesting under a registered plan with payment characterized as services rendered, indicating standard compensation practice. The notice includes broker details and an attestation that the seller is unaware of undisclosed material adverse information. Absent additional disclosures about related-party transfers, accelerated vesting, or unusual timing around material events, this filing presents as a routine insider disclosure rather than a governance red flag.
ANI Pharmaceuticals (ANIP) 鈥� Il modulo Form 144 indica la proposta di vendita di 14.675 azioni ordinarie tramite Morgan Stanley Smith Barney, per un valore complessivo di mercato di $1.304.170,19, con data di vendita prevista intorno al 18/08/2025. L'emittente ha in circolazione 21.688.772 azioni. La comunicazione specifica i dettagli di acquisizione dei titoli venduti: 1.072 azioni maturate il 20/12/2021, 3.554 azioni maturate il 31/08/2022 e 10.049 azioni maturate il 09/05/2023, tutte descritte come azioni vincolate maturate nell'ambito di un piano registrato per prestazioni rese. Il documento registra inoltre una vendita effettuata il 18/08/2025 da Jeanne A. Thoma di 6.865 azioni per proventi lordi di $616.223,68. Il dichiarante attesta l'assenza di informazioni materiali avverse non divulgate.
ANI Pharmaceuticals (ANIP) 鈥� El Formulario 144 muestra una propuesta de venta de 14.675 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney, con un valor de mercado agregado de $1.304.170,19, y una fecha aproximada de venta del 18/08/2025. El emisor tiene 21.688.772 acciones en circulaci贸n. La presentaci贸n detalla la adquisici贸n de los valores vendidos: 1.072 acciones adquiridas el 20/12/2021, 3.554 acciones adquiridas el 31/08/2022 y 10.049 acciones adquiridas el 09/05/2023, todas descritas como acciones restringidas que vencen bajo un plan registrado por servicios prestados. El documento tambi茅n registra una venta el 18/08/2025 por parte de Jeanne A. Thoma de 6.865 acciones por ingresos brutos de $616.223,68. El declarante afirma que no existen informaciones materiales adversas no divulgadas.
ANI Pharmaceuticals (ANIP) 鈥� Form 144鞐愲姅 Morgan Stanley Smith Barney毳� 韱淀暣 14,675 氤错喌欤茧ゼ 毵り皝頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜臧� $1,304,170.19, 鞓堨儊 毵り皝鞚检潃 2025-08-18搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氚滍枆欤茧姅 齑� 21,688,772欤检瀰雼堧嫟. 鞝滌稖靹滊鞐愲姅 毵り皝霅橂姅 歃濌秾鞚� 旆摑 雮挫棴鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟: 1,072欤�(2021-12-20 旆摑), 3,554欤�(2022-08-31 旆摑), 10,049欤�(2023-05-09 旆摑)搿�, 氇憪 靹滊箘鞀� 鞝滉车鞚� 雽�臧�搿� 霌彪霅� 頂岆灉鞐� 霐半澕 鞝滍暅欤缄皜 氩犾姢韺呺悳 瓴冹溂搿� 靹る獏霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 臧欖潃 靹滊鞐� Jeanne A. Thoma臧� 2025-08-18鞐� 6,865欤茧ゼ 毵り皝頃橃棳 齑� 靾橃澋 $616,223.68鞚� 鞏混棃雼り碃 旮半霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 歆勳垹頃╇媹雼�.
ANI Pharmaceuticals (ANIP) 鈥� Le formulaire 144 indique une proposition de vente de 14 675 actions ordinaires via Morgan Stanley Smith Barney, pour une valeur de march茅 totale de $1 304 170,19, et une date approximative de vente au 18/08/2025. L'茅metteur compte 21 688 772 actions en circulation. Le d茅p么t pr茅cise les modalit茅s d'acquisition des titres c茅d茅s : 1 072 actions acquises le 20/12/2021, 3 554 actions acquises le 31/08/2022 et 10 049 actions acquises le 09/05/2023, toutes d茅crites comme des actions restreintes acquises dans le cadre d'un plan enregistr茅 pour prestations de services. Le dossier enregistre 茅galement une vente le 18/08/2025 par Jeanne A. Thoma de 6 865 actions pour un produit brut de $616 223,68. Le d茅clarant atteste qu'il n'existe aucune information d茅favorable mat茅rielle non divulgu茅e.
ANI Pharmaceuticals (ANIP) 鈥� Das Formular 144 zeigt einen geplanten Verkauf von 14.675 Stammaktien 眉ber Morgan Stanley Smith Barney mit einem gesamten Marktwert von $1.304.170,19 und einem voraussichtlichen Verkaufstermin um den 18.08.2025. Der Emittent hat 21.688.772 ausstehende Aktien. Die Einreichung listet Erwerbsdetails der verkauften Wertpapiere auf: 1.072 Aktien, erworben am 20.12.2021; 3.554 Aktien, erworben am 31.08.2022; und 10.049 Aktien, erworben am 09.05.2023 鈥� alle als eingeschr盲nkte Aktien beschrieben, die unter einem registrierten Plan f眉r erbrachte Dienstleistungen vesten. Die Einreichung verzeichnet zudem einen Verkauf am 18.08.2025 durch Jeanne A. Thoma von 6.865 Aktien f眉r Bruttoerl枚se von $616.223,68. Der Einreicher versichert, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
FAQ
What securities does the ANIP Form 144 propose to sell?
When is the approximate sale date listed on the ANIP Form 144?
How were the ANIP shares being sold acquired?
Who is the broker handling the proposed ANIP sale?
Did the filer report any recent sales of ANIP shares?
